Study on the Effect of Online Cognitive Training Doses on Cognitive Function in Individuals With Mild Cognitive Decline

NCT ID: NCT07213362

Last Updated: 2025-10-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

234 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-08

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary questions that this clinical trial aims to answer are:

To compare the differences in the efficacy of different doses of Computerized Cognitive Training (CCT) in improving cognitive function among patients with Mild Cognitive Impairment (MCI), and to explore the potential optimal intervention dose.

To analyze the interaction between individual characteristics and the intervention dose of CCT.

To compare the improvement in functional activity ability of MCI patients among different CCT intervention dose groups.

To compare the symptoms of depression and anxiety among different CCT intervention dose groups.

To evaluate the adherence to different doses of CCT intervention.

Participants will:

Receive CCT intervention at varying durations and frequencies over a 12-week period, and will be followed up for cognitive function, functional activity ability, etc., at weeks 4, 12, and 24.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: 30 min/session × 3 sessions/week

CCT Training, 30 minutes per session, 3 times a week, for a total of 12 weeks

Group Type ACTIVE_COMPARATOR

Computerized Cognitive Training

Intervention Type DEVICE

Computerized Cognitive Training (30 minutes per session, 3 sessions per week, for a 12-week period)

Group 2: 45 min/session × 5 sessions/week

CCT Training, 45 minutes per session, 3 times a week, for a total of 12 weeks

Group Type ACTIVE_COMPARATOR

Computerized Cognitive Training

Intervention Type DEVICE

Computerized Cognitive Training (45 minutes per session, 3 sessions per week, for a 12-week period)

Group 3: 60 min/session × 5 sessions/week

CCT Training, 60 minutes per session, 3 times a week, for a total of 12 weeks

Group Type ACTIVE_COMPARATOR

Computerized Cognitive Training

Intervention Type DEVICE

Computerized Cognitive Training (60 minutes per session, 3 sessions per week, for a 12-week period)

Group 4: 30 min/session × 5 sessions/week

CCT Training, 30 minutes per session, 5 times a week, for a total of 12 weeks

Group Type ACTIVE_COMPARATOR

Computerized Cognitive Training

Intervention Type DEVICE

Computerized Cognitive Training (30 minutes per session, 5 sessions per week, for a 12-week period)

Group 5: 45 min/session × 5 sessions/week

CCT Training, 45 minutes per session, 5 times a week, for a total of 12 weeks

Group Type ACTIVE_COMPARATOR

Computerized Cognitive Training

Intervention Type DEVICE

Computerized Cognitive Training (45 minutes per session, 5 sessions per week, for a 12-week period)

Group 6: 60 min/session × 5 sessions/week

CCT Training, 60 minutes per session, 5 times a week, for a total of 12 weeks

Group Type ACTIVE_COMPARATOR

Computerized Cognitive Training

Intervention Type DEVICE

Computerized Cognitive Training (60 minutes per session, 5 sessions per week, for a 12-week period)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Computerized Cognitive Training

Computerized Cognitive Training (30 minutes per session, 3 sessions per week, for a 12-week period)

Intervention Type DEVICE

Computerized Cognitive Training

Computerized Cognitive Training (45 minutes per session, 3 sessions per week, for a 12-week period)

Intervention Type DEVICE

Computerized Cognitive Training

Computerized Cognitive Training (60 minutes per session, 3 sessions per week, for a 12-week period)

Intervention Type DEVICE

Computerized Cognitive Training

Computerized Cognitive Training (30 minutes per session, 5 sessions per week, for a 12-week period)

Intervention Type DEVICE

Computerized Cognitive Training

Computerized Cognitive Training (45 minutes per session, 5 sessions per week, for a 12-week period)

Intervention Type DEVICE

Computerized Cognitive Training

Computerized Cognitive Training (60 minutes per session, 5 sessions per week, for a 12-week period)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 60 years.
* Self-reported cognitive decline, confirmed by an informant.
* Montreal Cognitive Assessment (MoCA) score of 19-25, adjusted for years of education (+1 point for 12 years or less).
* Ability to complete activities of daily living independently.
* Possesses basic communication skills and is able to cooperate with the study procedures.
* Voluntarily agrees to participate in the study and signs the informed consent form.

Exclusion Criteria

* Presence of underlying neurological diseases that may impair cognitive function, including but not limited to dementia syndrome, Parkinson's disease, epilepsy, and cerebrovascular disease.
* Presence of severe or unstable organic diseases such as cancer, hydrocephalus, history of central nervous system tumors, or acute brain injury/infection.
* Diagnosis of severe mental illness such as major depressive disorder, schizophrenia, schizoaffective disorder, or bipolar disorder.
* Presence of severe visual or hearing impairment, or other physical conditions that may interfere with the completion of the study.
* Participation in any other clinical trial within the past 3 months.
* Having received transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), light therapy, or having taken medications that could significantly affect cognitive function (e.g., nootropics, psychoactive drugs, anticholinergic drugs, benzodiazepines) for any reason within the past 6 months.
* History of alcohol dependence or substance abuse.
* Consumption of alcohol or other substances that affect cognitive function, such as caffeine or cocaine, within 24 hours prior to the cognitive assessment.

Any other conditions that the investigator deems unsuitable for participation in this study.
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Haibo Wang

Research Fellow

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Haibo Wang

Role: CONTACT

+8613521204583

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB00001052-25101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.